Nitrosamine Formation in Solid Drug Products

R


R2

Dr Garry Scrivens FreeThink Webinar Series 2023




Introduction

- Observation of N-nitrosamines in "sartans" (July–Dec. 2018)
- Recalls of certain pharmaceutical products across industry
- Observation that nitrites are found at various levels (ppm levels) in some excipients not on CofA
 - \Rightarrow APIs containing a secondary amine group need to be assessed




- Certain nitrosamines are 'cohort of concern' compounds
- Much of our understanding about the formation of nitrosamines comes from solution chemistry
- Much less is known about their formation in solid products the focus of this presentation
- The aim of the work presented here is to ensure that nitrosamine risk assessments are based on the best possible underlying scientific understanding.






Nitrosamine Formation Mechanism In Solution

Simplified General Equation:



- Overall stoichiometry: 1 amine + 1 nitrite → 1 nitrosamine
- In aqueous solution, the actual nitrosating species is a combination of different species:




The reaction mechanism requires both the nitrite and the amine to be **non-ionised**:


```
HNO<sub>2</sub> R<sub>2</sub>NH
```

Therefore the reaction rate is highly pHdependent and highly dependent on the pKa of the amine


Nuc: e.g. Cl⁻ or other halides Actual Nitrosating Species

Nitrosamine Formation in Aqueous Solution: Dependence on Solution pH and pKa of Amine











4

Nitrites in Excipients

- · Compendial specifications and CofAs for excipients do not currently include nitrite levels
- Nitrites are found at low (ppm, ppb) levels in many excipients
- Industry consortium to generate an excipient nitrite database (Lhasa)

CAS Number	Excipient name	Structure LUID Common Name	LUID	Nitrite LOQ (ug/g)	Nitrite result (u	g/g) Da	ite of manufacture	Date of te	st Suppl
55589-62-3	Acesulfame potassium	38205053 Acesulfame potassium	38327451	<0.1	LLOQ		Jan-20	Nov-	20 BUO
55589-62-3	Acesulfame potassium	38205053 Acesulfame potassium	38205066	5 <0.10	LLOQ		Jul-19	Jul-	20 BUO
55589-62-3	Acesulfame potassium	38205053 Acesulfame potassium	38205065	i <0.10	LLOQ		Jan-19	Jul-	20 BUO
55589-62-3	Acesulfame potassium	38205053 Acesulfame potassium	38205064	<0.10	LLOQ		Apr-18	3 Jul-	20 BUO
77-92-9	Anhydrous citric acid	40602647 Anhydrous citric acid	40602654	<0.10	LLOQ		Oct-19	Jul-	20 CAX
7757-93-9	Anhydrous dibasic calcium phosphate	37350051 Anhydrous dibasic calcium phosphate	37350053	0.1		0.41	Nov-18	B May-	20 BXV
7757-93-9	Anhydrous dibasic calcium phosphate	37350051 Anhydrous dibasic calcium phosphate	37350052	2 0.1		0.17	Jun-18	B May-	20 BXV
63-42-3	Anhydrous lactose	37350182 Anhydrous lactose	40503551	0.02	Not detected		Nov-19	Nov-	20 ZFC
63-42-3	Anhydrous lactose	37350182 Anhydrous lactose	37350192	. 0.5	Not detected		Aug-19	Aug-	20 UXA
63-42-3	Anhydrous lactose	37350182 Anhydrous lactose	37350191	. 0.5	Not detected		Dec-18	B Aug-	20 UXA
63-42-3	Anhydrous lactose	37350182 Anhydrous lactose	37350190	0.5	Not detected		Apr-19	Aug-	20 UXA
74-79-3	Arginine	40546703 Arginine	40546704	0.1		0.16	Mar-1	7 Nov-	20 MKJ
50-81-7	Ascorbic acid	38205054 Ascorbic acid	38205068	3 <0.10	LLOQ		Nov-18	Aug-	20 PUF
50-81-7	Ascorbic acid	38205054 Ascorbic acid	38205067	/ <0.10	LLOQ		May-19	Aug-	20 PUF
22839-47-0	Aspartame	38205055 Aspartame	38205071	<0.10	LLOQ		Apr-20) Jul-	20 HMF
22839-47-0	Aspartame	38205055 Aspartame	38205070	0 <0.10	LLOQ		Jul-1	5 Jul-	20 HMF
22839-47-0	Aspartame	38205055 Aspartame	38205069	0 <0.10	LLOQ		Mar-13	Jul-	20 HMF
9004-32-4	Carboxymethylcellulose sodium	37499018 Carboxymethylcellulose sodium	37723404	0.04	LLOQ		Jan-19	Oct-	20 EZH
9004-32-4	Carboxymethylcellulose sodium	37499018 Carboxymethylcellulose sodium	37723403	0.04	LLOQ		Jan-19	Oct-	20 EZH
9004-32-4	Carboxymethylcellulose sodium	37499018 Carboxymethylcellulose sodium	37499026	5 10	Not detected	No	ot specified	XXX2014	OWZ
9004-32-4	Carboxymethylcellulose sodium	37499018 Carboxymethylcellulose sodium	37499025	5 10	Not detected	No	ot specified	XXX2014	111
8015-86-9	Carnauba wax	38205118 Carnauba wax	38205134	0.11		0.21	Jun-16	6 Oct-	20 BUO
9004-35-7	Cellulose acetate	38104182 Cellulose acetate	38194559	0.1	LLOQ	XX	X2016	Jun-	20 QVJ
5949-29-1	Citric acid monohydrate	38205056 Citric acid monohydrate	38205073	3 <0.10	LLOQ		Nov-1	7 Aug-	20 RVN
5949-29-1	Citric acid monohydrate	38205056 Citric acid monohydrate	38205072	2 <0.10	LLOQ		Dec-18	B Aug-	20 RVN
	Coating: hypromellose	38140392 Coating: hypromellose	40546707	0.05	LLOQ		Jan-20) Feb-	21 VYV
	Coating: hypromellose	38140392 Coating: hypromellose	40546706	0.05	LLOQ		Apr-20	Feb-	21 VYV
	Coating: hypromellose	38140392 Coating: hypromellose	40546705	0.05	LLOQ		Feb-20	Feb-	21 VYV
	Coating: hypromellose	38140392 Coating: hypromellose	38205139	0.22		0.28	Oct-18	Oct-	20 VYV

Etc....currently >400 entries in Lhasa database








The Nature of Nitrites: Varying Nitrite levels


Lab-scale:



Fluid Bed Study


Pilot-scale:


- Detailed Studies on MCC
- Similar observations with Lactose



The Nature of Nitrites: Volatility, Effect of Temperature and Humidity

Initially, it was believed that higher temperatures would drive off the volatile species...






- * Conditions have same absolute humidity of 11.6 mg water per litre of air
- † Absolute humidity = ~0.6 mg/L


Conclusion: <u>Relative</u> Humidity is Key

Temperature is of secondary importance



The Nature of Nitrites: Nitrosation of API via Volatile Species






Also: Examples of API forming nitrosamine when dried in an oven also containing an excipient with high nitrite levels

Breakthroughs that change patients' lives

The Nature of Nitrites: Volatile Nitrosating Species: Air Quality (NO_X)

A reactive secondary amine API on open bench (Chennai Study):






Nitrosamine Formation in Solid State Drug Products

- Mechanisms
- Factors affecting rate and extent of formation (T & RH)






Prizer Breakthroughs that change patients' lives


Nitrite Levels (Analytical Results) vs Nitrosation Potential

- Is all nitrite 'available' to react?
- The "Nitrite" species interconvert:
 - In the aqueous environments of the analytical method, all nitrosating species are probably quantified together as "nitrite"
 - If the "nitrite" is present as (e.g.) nitrite esters in excipient, these could rapidly convert to reactive nitrosating species or nitrosate amines directly






Competing Reactions...and Plateauing Nitrosamine Formation




Plateauing Behaviour is Observed:

- This is to be expected: finite source of reactive limiting reagent (nitrite) available to the amine
- In the systems we studied, Plateau Level (PL) is more important than 'rate' for assessing drug product nitrosamine risk (because PL will typically be reached within <12 months at 25°C/60%RH)
- The observed plateau level is linked to the amount of reactive limiting reagent (nitrite) and the relative rates of "Loss" vs reaction with amine






Effect of Temperature and Humidity on Nitrosamine Formation in Solid State



Nitrosamine - Water Activity (a_w) Trend



The observed 'exponential' trend between nitrosamine and water activity is reminiscent of the 'ASAP' humidity-modified Arrhenius relationship and consistent with the high-level model for humidity (previous slide)

Breakthroughs that change patients' lives

Water Activity

Nitrosamine ("ASAP")

(Accelerated Stability Assessment Protocols)



ASAP Studies

- ASAP studies have been an essential tool for providing a rapid estimation of long-term nitrosamine levels
 - At room temperature, it takes >6 months for the plateau level to be measured/estimated (API Dependent)
- 'Standard' ASAP protocols may not be applicable
 - The volatility of the reactants mean 'open' containers inside humidity-controlled ovens would lead to falsely-low results (as discussed above).
 - The use of saturated salt solutions inside airtight containers to control humidity also may not be suitable (if the salt solution acts as a 'sink' for the volatile species e.g. alkaline salt solutions).
- Sample Handling can affect results
 - Prior storage, ventilation and container material can affect the nitrosamine levels; this extends to manufacturing processes such as film coating

	Airtight conta	ainer	
RH in vial can be adjusted by adding very small amounts of water to the weighting boat via a microsyringe. The amount of water added is calculated from the product's moisture sorption isotherm. The water rapidly disperses amongst product and the resulting RH in vial is verified by an RH probe.		T&RH Probe Weighing boat separates the added water from the product Product	7 and 14 days at 60°C* * Other temperatures and timepoints can be used if necessary for maintaining the product in its intended form


A · · · I · · · ·



ASAP Studies


Experimental data so far indicate elevated temperatures:

- Accelerate nitrosamine formation
- Do not significantly affect plateau level





ASAP Studies: Comparisons with Long-Term Data:



6 batches:

- All contain antioxidant
- 2 strengths
- Different levels of nitrite across the lots
- 2 types of packaging



Breakthroughs that change patients' lives

- ASAP data correlate well with long-term data
- ASAP data are consistently 1-2 ppm higher than the long-term data
 - \Rightarrow Provides realistic worst case.
 - ⇒ Long-term data may not have fully reached plateau level
 - ⇒ The use of a less permeable container in ASAP may prevent loss of volatile nitrosating species


API Reactivity


- Chemical Reactivity
 - pKa
 - Aryl vs Alkyl amines
- API Reactivity Screening
- Salt Form / Solid Form



API Reactivity

- In Solids:
 - API reactivity will affect both rate and extent of nitrosamine formation
 - Additional considerations such as particle size, surface area and degree of disorder are also likely to be important








API Reactivity

- "NAP" test and "IQ conditions" can be used to assess API potential to form nitrosamines: these
 are solution-based conditions (rate influenced by pKa, pH, temperature, structure of amine etc.)
- In solids, additional considerations such as solid form, choice of salt / free base, particle size, surface area and degree of disorder are also <u>key</u> in determining API reactivity – these factors are invisible to the solution-based tests.




Formulation Investigations

- Nitrites in excipients \rightarrow nitrosamine levels
- Comparison of API:Excipient binary mixtures
 with multicomposite formulations
- "Activating" excipients
- (Effect of drug load)



Nitrosation by Individual Excipients (Binary mixtures)



Each datapoint is a different excipient

Nitrosamine Level (y-axis) is the maximum level reached (i.e. plateau level) obtained from accelerated studies


Correlation between ingoing excipient nitrite level and resulting nitrosamine level $(R^2) = 0.79$

<100% Conversion of nitrite – helpful to know for nitrosamine risk assessments based on nitrite levels


Wide range of nitrite→nitrosamine conversion levels observed

From Binary Mixtures to Multicomponent Mixtures

Multicomponent mixtures may behave 'as expected' based on the ingoing individual excipients (i.e. a linear combination of the amounts expected from binary mixtures):



Nitrosamine levels in multicomponent mixtures are sometimes different from the levels that may be expected from the binary mixtures of ingoing individual excipients




Why?

- Localized pH? E.g. acidity of Prosolv (SiO₂) activates nitrites in lactose?
- Water activity differences?
- Minor components ("other") may be ionic (=> interact with API salt)?
- Excipients with different particle sizes, surface areas and nitrite "availabilities"?

High pH formulations for controlling nitrosamines

May be effective for solution-phase products For solid dosage forms...?



High pH Formulation:

- 'Alkaline' excipients may have high nitrite levels (may trap 'NOx' as nitrite)
- Non-protonated amines (i.e. free base) more readily form nitrosamines than salts
- Mixing 'alkaline' excipients with API-salts could lead to salt disproportionation


Summary: Reducing Potential for Nitrosamine Formation in Drug Products

- Antioxidants
- Low Nitrite Excipients and Suppliers
- Desiccants
- API Salt Selection
- Other Strategies




Antioxidants / Inhibitors

- The effectiveness of the antioxidant is API dependent
- Caution: discolouration may be an issue with antioxidants



API "A". Antioxidant added as dry powder





Summary

Progress in Understanding Mechanisms:

- Relationship between nitrite and nitrosamine levels
- Not all amines nitrosate. Nitrosation tests have important role in understanding reactivity.
- Volatility, mobility and reactivity of nitrites and nitrosating species
- Factors that affect %conversion of nitrite into nitrosamines: API reactivity, drug load, humidity, temperature, activating excipients
- Differences between solid and solutionphase dosage forms

Nitrosamine Reduction:

- Low nitrite drug product platforms: low nitrite excipients
- Desiccants
- Antioxidants
- API salt and solid form selection (evaluated by solid-state nitrosation test)
- Processes for reducing nitrité levels in excipients

Thank You For Your Attention



Acknowledgements

Garry O'Connor Greg Sluggett Olivier Dirat John Agbike Shrina Bhagat Atul Awasthi Fiona Clarke Sally Grieb Rand Turki Alan Carmody Rozee Ali

Pfizer

